Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. [electronic resource]
Producer: 20200914Description: 4624-4633 p. digitalISSN:- 1557-3265
- Abiraterone Acetate -- administration & dosage
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- pharmacokinetics
- Benzamides -- administration & dosage
- HSP90 Heat-Shock Proteins -- antagonists & inhibitors
- Humans
- Isoindoles -- administration & dosage
- Male
- Middle Aged
- Patient Safety
- Prednisolone -- administration & dosage
- Prostatic Neoplasms, Castration-Resistant -- drug therapy
- Survival Rate
- Tissue Distribution
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.